RBOT — Vicarious Surgical Inc.

Vicarious Surgical Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Operating Expenses: $11.5 million, down 35% from $17.8 million in Q3 2024.
• Research and Development Expenses: $8 million, decreased from $10.8 million in Q3 2024.
• General and Administrative Expenses: $3.2 million, down from $5.7 million in Q3 2024.
• Sales and Marketing Expenses: $350,000, reduced from $1.2 million in Q3 2024.
• GAAP Net Loss: $11.1 million ($1.86 per share), improved from a loss of $17.1 million ($2.90 per share) in Q3 2024.
• Non-GAAP Adjusted Net Loss: $11.3 million ($1.91 per share), compared to $17 million ($2.87 per share) in Q3 2024.
• Cash Position: $13.4 million at the end of Q3 2025, with a cash burn rate of approximately $10.5 million.
• Full Year 2025 Cash Burn Expectation: Approximately $50 million.

2. Strategic Updates and Business Highlights:

• Design Freeze Target: Aiming for completion of the production-equivalent system by year-end 2026, which is critical for clinical entry and commercialization.
• Cost Reduction Initiatives: Implemented measures to reduce cash burn, including restructuring teams and reducing headcount by about 15%.
• Outsourcing Strategy: Engaged a consulting firm to evaluate outsourcing opportunities to enhance capital efficiency while preserving core technology.
• Communication Improvements: Plans to provide regular updates on development progress through social media and the Investor Relations website.

3. Forward Guidance and Outlook:

• Cash Burn Reduction: Focused on achieving a material reduction in cash burn for 2026 and beyond.
• Consulting Engagement: Expected to complete the outsourcing analysis by the end of November 2025, with RFPs to follow.
• Ongoing Development: Committed to maintaining momentum towards design freeze despite potential disruptions from outsourcing.

4. Bad News, Challenges, or Points of Concern:

• Cash Burn Rate: While reduced, the current cash burn remains significant, necessitating ongoing efforts to lower expenses.
• Outsourcing Risks: Potential disruptions during the outsourcing process could impact timelines, although management aims to mitigate these risks through proactive communication.
• Employee Layoffs: A recent layoff of 15% of employees indicates challenges in managing operational costs effectively.

5. Notable Q&A Insights:

• Timeline Confirmation: Management confirmed that the timeline for achieving design freeze remains targeted for mid-2026, despite potential disruptions from outsourcing.
• Surgeon Engagement: Continuous testing with surgeons is being conducted, showing promising improvements in system stability and efficiency, particularly in surgical procedures.
• Strong Hospital Relationships: Ongoing communications with hospital partners remain robust, with positive feedback from surgeons involved in testing.

Overall, Vicarious Surgical is focused on strategic cost reductions and maintaining development timelines while enhancing communication with stakeholders. However, challenges related to cash burn and the outsourcing process remain key areas of concern.